12-month observational study results presented
at the International Pain Conference in Colombia on September
25th, 2021
- 1st research study of its kind with a significant
patient base for medical cannabis in LatAm
- 1,453 patients in 12-month period, serviced at Khiron's Zerenia
clinics in Colombia, using
Khiron's CBD and THC oral sublingual medical cannabis oils
- 80% patients with positive clinic response for chronic pain,
nausea, insomnia, anxiety, spasticity and depression
TORONTO, Oct. 7, 2021 /CNW/ - Khiron Life Sciences Corp.
("Khiron" or the "Company") (TSXV: KHRN)(OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated
international cannabis leader with core operations in Latin America and Europe, is pleased to announce that the
Company presented results from its first research study including
1,453 patients from Khiron-owned Zerenia Clinics at the
29th International Pain Conference in Barranquilla,
Colombia, organized by ACED, the
Colombian chapter of the International Association for the Study of
Pain (IASP).
The study, entitled "Prescription patterns and clinical outcomes
in a cohort of patients receiving progressive therapy with
cannabinoids for medical use in Colombia", is a longitudinal, retrospective
cohort study including 1,453 patients receiving treatment with
medical cannabis at Khiron-owned clinics in Colombia, Zerenia and ILANS.
The scope of research was to capture patient-reported outcome
measures (PROMS) and patient-reported experience measures (PREMS)
of general efficacy, adherence, and side effects of oral
formulations ranging in cannabinoid content for the treatment of
different health conditions with a diverse patient base over a
twelve-month period.
The research protocol was reviewed and approved by the
Scientific Institutional Committee and the Research Ethical
Committee of the Universidad del Bosque, in Colombia, one of the leading institutions on
medical research in the region.
Demographic results reported most patients were female (73%)
with and average age of 59.3 years old, which is in strong contrast
with results arising from Project T21, the UK's first medical
cannabis registry Khiron Life Sciences has been supporting since
its foundation in 2019. Patients in the study were mainly diagnosed
with chronic, non-cancer pain (77%), followed by nausea and
vomiting (8%), insomnia (6%), anxiety (5%), spasticity and
depression, among others and up to 68 % of patients had their
medical cannabis prescription cost covered by the Social Security
in Colombia. Study results show a
patient-reported positive clinic response in more than 80% of
participants with only minor side-effects associated to the
treatment.
Management Commentary
"Scientific research and data
are key to convincing doctors and policy makers all over the world
about the benefits of medical cannabis to treat conditions that are
prevalent in every society and market we are targeting. After one
year of compiling information and having gone through a very
detailed approval process, we are very proud to share the results
from this first-of-its-kind clinical study in Latin America with such a significant patient
base. This is just the beginning of our ongoing research program.
We are looking forward to sharing the outcomes of this first cohort
study with the international medical audience through
peer-reviewed, specialized publications so doctors all over the
world can continue to drive prescription growth safely and
responsibly ", commented Alvaro
Torres, Chief Executive Officer and Director of the
Company.
About Khiron Life Sciences Corp.
Khiron is a leading
vertically integrated international medical cannabis company with
core operations in Latin America
and Europe. Leveraging
wholly-owned medical health clinics and proprietary telemedicine
platforms, Khiron combines a patient-oriented approach, physician
education programs, scientific expertise, product innovation, and
agricultural infrastructure to drive prescriptions and brand
loyalty with patients worldwide. The Company has a sales presence
in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in
Mexico. The Company is led by
Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and
diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and
Linkedin at
https://www.linkedin.com/company/khiron-life-sciences-corp/
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in
respect of Khiron, its securities, or financial or operating
results (as applicable). Although Khiron believes that the
expectations reflected in forward-looking statements in this press
release are reasonable, such forward-looking statement has been
based on expectations, factors and assumptions concerning future
events which may prove to be inaccurate and are subject to numerous
risks and uncertainties, certain of which are beyond Khiron's
control, including the risk factors discussed in Khiron's Annual
Information Form which is available on Khiron's SEDAR profile at
www.sedar.com. The forward-looking information contained in this
press release is expressly qualified by this cautionary statement
and is made as of the date hereof. Khiron disclaims any intention
and has no obligation or responsibility, except as required by law,
to update or revise any forward-looking information, whether as a
result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/khiron-presents-its-first-research-study-with-1-400-patients-301394865.html
SOURCE Khiron Life Sciences Corp.